Stephens resumed coverage of Alpha Teknova (TKNO) with an Overweight rating and $8 price target The company will benefit from growth in the biologics end market, the analyst tells investors in a research note. The firm believes Alpha continues to add to its clinical solutions customer base, which should drive revenue growth as demand ramps.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TKNO: